ArticleACS omega2017
Resolution of Racemic Mixtures by Phase Transition of PEGylated Resolving Agents.
Article in ACS omega, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel, efficient, and simple method for the resolution of racemic mixtures is presented in which PEGylated resolving agents are subjected to diastereomeric complex formation in alcohols. The resulting complexes then undergo temperature-assisted phase transition, affording a precipitate that is enriched in one enantiomer and separable by filtration. In an aqueous solution, phase transition can be caused by the methods used in the precipitation of poly(ethylene glycol) (e.g., addition of ammonium sulfate). A number of racemic amines have been successfully resolved using this method. The first cycle of resolution affords the amines with an optical purity of 72-85% from their corresponding racemic mixture in good yields (78-90%). An additional cycle improved the optical purity to 87-95%. The PEGylated resolving agents can be recovered and reutilized without the loss of resolution efficiency.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.